Beyond the classical: Influenza virus and the elucidation of alternative MHC class II-restricted antigen processing pathways

Immunologic Research

Volumn 51, Issue 2-3, 2011, Pages 237-248

  Eisenlohr, Laurence C ^a,b   Luckashenak, Nancy ^a   Apcher, Sebastien ^a   Miller, Michael A ^a   Sinnathamby, Gomathinayagam ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b BLSB   (United States)

Author keywords

Antigen presentation; Antigen processing; Endogenous; Exogenous; Influenza; Major histocompatibility class II

Indexed keywords

BREFELDIN A; HEMAGGLUTININ; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; NUCLEOPROTEIN; PRIMAQUINE; PROTEASOME INHIBITOR; SIALIDASE;

ACCESSORY CELL; AMINO ACID ANALYSIS; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ARTICLE; AUTOIMMUNE DISEASE; B LYMPHOCYTE; BINDING KINETICS; CARBOXY TERMINAL SEQUENCE; CD4+ T LYMPHOCYTE; COMPETITIVE INHIBITION; DISULFIDE BOND; ENDOCYTOSIS; ENDOPLASMIC RETICULUM; ENDOSOME; ENZYME LINKED IMMUNOSPOT ASSAY; INFLUENZA; INFLUENZA VIRUS; MACROPHAGE; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; MOLECULAR RECOGNITION; NONHUMAN; OPEN READING FRAME; PEPTIDE MAPPING; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN MODIFICATION; PROTEIN MOTIF; PROTEIN PURIFICATION; PROTEIN STABILITY; PROTEIN SYNTHESIS; T LYMPHOCYTE ACTIVATION;

ANIMALS; ANTIGEN PRESENTATION; ANTIGENS, VIRAL; CD4-POSITIVE T-LYMPHOCYTES; ENDOSOMES; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; INFLUENZA, HUMAN; INTRACELLULAR SPACE; MICE; ORTHOMYXOVIRIDAE; ORTHOMYXOVIRIDAE INFECTIONS;

EID: 84856544691     PISSN: 0257277X     EISSN: 15590755     Source Type: Journal    
DOI: 10.1007/s12026-011-8257-3     Document Type: Article

References (142)

1. Black CA. Delayed type hypersensitivity: Current theories with an historic perspective. Dermatol Online J. 1999;5:7.
2. Landsteiner K, Chase MW. Experiments on transfer of cutaneous sensitivity to simple compounds. Proc Soc Exp Biol Med. 1942;49:688-90.
3. Waksman BH. Cellular hypersensitivity and immunity: Conceptual changes in last decade. Cell Immunol. 1979;42:155-69. (Pubitemid 9138585)
4. Burke DS. Of postulates and peccadilloes: Robert Koch and vaccine (tuberculin) therapy for tuberculosis. Vaccine. 1993;11:795-804. (Pubitemid 23180236)
5. Kaufmann SHE. Robert Koch's highs and lows in the search for a remedy for tuberculosis. In: Nat Med. 2000. http://www. nature.com/nm/focus/tb/historical- perspective.html.
6. Dienes L, Schoenheit EW. The reproduction of tuberculin hypersensitiveness in guinea pigs with various protein substances. Am Rev Tuberc. 1929;20:92-105.
7. Becker EL, Munoz J. Studies on the antigenicity of cytochrome c. J Immunol. 1949;63:173-81.
8. Goncalves JM, Molinari R, Deutsch HF. Chromatographic and immunochemical studies on lysozyme. Arch Biochem Biophys. 1956;60:171-9.
9. Reichlin M, Hay M, Levine L. Immunochemical studies of hemoglobin and myoglobin and their globin moieties. Biochemistry. 1963;2:971-9.
10. Marrack P, Graham SD Jr, Leibson HJ, Roehm N, Wegmann D, Kappler JW. Properties of H-2 restricted T cell hybridomas. In: Fathman CG, Fitch FW, editors. Isolation, characterization, and utilization of T lymphocyte clones. New York: Academic Press, Inc; 1982. p. 119-26.
11. Miller JF, Morahan G, Slattery R, Allison J. Transgenic models of T-cell self tolerance and autoimmunity. Immunol Rev. 1990; 118:21-35.
12. Zhong G, Reis e Sousa C, Germain RN. Production, specificity, and functionality of monoclonal antibodies to specific peptidemajor histocompatibility complex class II complexes formed by processing of exogenous protein. Proc Natl Acad Sci USA. 1997;94:13856-61.
13. Janeway CA Jr. Approaching the asymptote? Evolution and revolution in immunology. Cold Spring Harb Symp Quant Biol. 1989;54(Pt 1):1-13. (Pubitemid 20177564)
14. Alter BJ, Bach FH. Lymphocyte reactivity in vitro. I. Cellular reconstitution of purified lymphocyte response. Cell Immunol. 1970;1:207-18.
15. Unanue ER. The regulation of lymphocyte functions by the macrophage. Immunol Rev. 1978;40:227-55. (Pubitemid 8347696)
16. Unanue ER. Antigen-presenting function of the macrophage. Annu Rev Immunol. 1984;2:395-428.
17. Chesnut RW, Grey HM. Studies on the capacity of B cells to serve as antigen-presenting cells. J Immunol. 1981;126:1075-9. (Pubitemid 11155757)
18. Lanzavecchia A. Antigen-specific interaction between T and B cells. Nature. 1985;314:537-9. (Pubitemid 15124262)
19. Grey HM, Chesnut R. Antigen processing and presentation to T cells. Immunol Today. 1985;6:101-6.
20. Malissen B, Price MP, Goverman JM, McMillan M, White J, Kappler J, Marrack P, Pierres A, Pierres M, Hood L. Gene transfer of H-2 class II genes: Antigen presentation by mouse fibroblast and hamster B-cell lines. Cell. 1984;36:319-27. (Pubitemid 14126223)
21. Norcross MA, Bentley DM, Marguilies DH, Germain RN. Membrane Ia expression and antigen-presenting accessory cell function of L cells transfected with class II major histocompatibility complex genes. J Exp Med. 1984;160:1316-37. (Pubitemid 15220765)
22. Lechler RI, Norcross MA, Germain RN. Qualitative and and quantitative studies of antigen-presenting cell function by using I-A-expressing L cells. J Immunol. 1985;135:2914-22. (Pubitemid 16250539)
23. Steinman RM, Nussenzweig MC. Dendritic cells: Features and functions. Immunol Rev. 1980;53:125-47.
24. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature. 1998;392:245-52. (Pubitemid 28155090)
25. Granucci F, Foti M, Ricciardi-Castagnoli P. Dendritic cell biology. Adv Immunol. 2005;88:193-233. (Pubitemid 41437915)
26. Sigmundsdottir H, Butcher EC. Environmental cues, dendritic cells and the programming of tissue-selective lymphocyte trafficking. Nat Immunol. 2008;9:981-7.
27. Lin ML, Zhan Y, Villadangos JA, Lew AM. The cell biology of cross-presentation and the role of dendritic cell subsets. Immunol Cell Biol. 2008;86:353-62. (Pubitemid 351667998)
28. Kisselev AF, Akopian TN, Woo KM, Goldberg AL. The sizes of peptides generated from protein by mammalian 26 and 20 S proteasomes. Implications for understanding the degradative mechanism and antigen presentation. J Biol Chem. 1999;274: 3363-71. (Pubitemid 29077173)
29. Watts C. Antigen processing in the endocytic compartment. Curr Opin Immunol. 2001;13:26-31. (Pubitemid 32096956)
30. Stern LJ, Potolicchio I, Santambrogio L. MHC class II compartment subtypes: Structure and function. Curr Opin Immunol. 2006;18:64-9. (Pubitemid 43049650)
31. Sercarz EE, Maverakis E. Mhc-guided processing: Binding of large antigen fragments. Nat Rev Immunol. 2003;3:621-9. (Pubitemid 37328665)
32. Wolf PR, Tourne S, Miyazaki T, Benoist C, Mathis D, Ploegh HL. The phenotype of H-2M-deficient mice is dependent on the MHC class II molecules expressed. Eur J Immunol. 1998;28: 2605-18. (Pubitemid 28425220)
33. Van Kaer L. Accessory proteins that control the assembly of MHC molecules with peptides. Immunol Res. 2001;23:205-14. (Pubitemid 32575361)
34. Jensen PE. Long-lived complexes between peptide and class II major histocompatibility complex are formed at low pH with no requirement for pH neutralization. J Exp Med. 1992;176:793-8.
35. Groothuis T, Neefjes J. The ins and outs of intracellular peptides and antigen presentation by MHC class I molecules. Curr Top Microbiol Immunol. 2005;300:127-48.
36. Braciale TJ, Yap KL. Role of viral infectivity in the induction of influenza virus-specific cytotoxic T cells. J Exp Med. 1978;147: 1236-52. (Pubitemid 8318089)
37. Germain RN. The ins and outs of antigen processing and presentation. Nature. 1986;322:687-9.
38. Lehner PJ, Cresswell P. Recent developments in MHC-class-Imediated antigen presentation. Curr Opin Immunol. 2004;16:82-9. (Pubitemid 38198121)
39. Cresswell P, Ackerman AL, Giodini A, Peaper DR, Wearsch PA. Mechanisms of MHC class I-restricted antigen processing and cross-presentation. Immunol Rev. 2005;207:145-57. (Pubitemid 41415014)
40. Wilson NS, Villadangos JA. Regulation of antigen presentation and cross-presentation in the dendritic cell network: Facts, hypothesis, and immunological implications. Adv Immunol. 2005;86:241-305. (Pubitemid 40215695)
41. Khor B, Makar RS. Toward a molecular explanation for crosspresentation of antigens to the immune system. Transfus Med Rev. 2008;22:188-201. (Pubitemid 351842623)
42. Eckert DM, Kim PS. Mechanisms of viral membrane fusion and its inhibition. Annu Rev Biochem. 2001;70:777-810. (Pubitemid 32662225)
43. Hurwitz JL, Hackett CJ, McAndrew EC, Gerhard W. Murine TH response to influenza virus: Recognition of hemagglutinin, neuraminidase, matrix, and nucleoproteins. J Immunol. 1985;134: 1994-8. (Pubitemid 15128974)
44. Gerhard W, Haberman AM, Scherle PA, Taylor AH, Palladino G, Caton AJ. Identification of eight determinants in the hemagglutinin molecule of influenza virus A/PR/8/34 (H1N1) which are recognized by class II-restricted T cells from BALB/c mice. J Virol. 1991;65:364-72.
45. Hackett CJ, Hurwitz JL, Dietzschold B, Gerhard W. A synthetic decapeptide of influenza virus hemagglutinin elicits helper T cells with the same fine recognition specificities as occur in response to whole virus. J Immunol. 1985;135:1391-4.
46. Hurwitz JL, Heber-Katz E, Hackett CJ, Gerhard W. Characterization of the murine TH response to influenza virus hemagglutinin: Evidence for three major specificities. J Immunol. 1984;133:3371-7. (Pubitemid 15216520)
47. Yoshikawa M, Watanabe M, Hozumi N. Analysis of proteolytic processing during specific antigen presentation. Cell Immunol. 1987;110:431-5. (Pubitemid 18031647)
48. Bland PW, Whiting CV. Antigen processing by isolated rat intestinal villus enterocytes. Immunology. 1989;68:497-502. (Pubitemid 20010007)
49. Wyss-Coray T, Brander C, Bettens F, Mijic D, Pichler WJ. Use of antibody/peptide constructs of direct antigenic peptides to T cells: Evidence for T cell processing and presentation. Cell Immunol. 1992;139:268-73.
50. Eisenlohr LC, Gerhard W, Hackett CJ. Individual class IIrestricted antigenic determinants of the same protein exhibit distinct kinetics of appearance and persistence on antigen-presenting cells. J Immunol. 1988;141:2581-4. (Pubitemid 18263037)
51. Neefjes JJ, Ploegh HL. Inhibition of endosomal proteolytic activity by leupeptin blocks surface expression of MHC class II molecules and their conversion to SDS resistance alpha beta heterodimers in endosomes. EMBO J. 1992;11:411-6.
52. Chianese-Bullock KA, Russell HI, Moller C, Gerhard W, Monaco JJ, Eisenlohr LC. Antigen processing of Two H2-IEd restricted epitopes is differentially influenced by the structural changes in a viral glycoprotein. J Immunol. 1998;161:1599-607. (Pubitemid 28387574)
53. Sinnathamby G, Maric M, Cresswell P, Eisenlohr LC. Differential requirements for endosomal reduction in the presentation of two H2-E(d)-restricted epitopes from influenza hemagglutinin. J Immunol. 2004;172:6607-14. (Pubitemid 38669095)
54. Watts C. Capture and processing of exogenous antigens for presentation on MHC molecules. Annu Rev Immunol. 1997;15:821-50. (Pubitemid 27169300)
55. van den Hoorn T, Paul P, Jongsma ML, Neefjes J. Routes to manipulate MHC class II antigen presentation. Curr Opin Immunol. 2011;23:88-95.
56. Martens S, McMahon HT. Mechanisms of membrane fusion: Disparate players and common principles. Nat Rev Mol Cell Biol. 2008;9:543-56. (Pubitemid 351881838)
57. Harrison SC. Viral membrane fusion. Nat Struct Mol Biol. 2008;15:690-8. (Pubitemid 351932011)
58. Falnes PO, Sandvig K. Penetration of protein toxins into cells. Curr Opin Cell Biol. 2000;12:407-13. (Pubitemid 30453589)
59. Shin JS, Ebersold M, Pypaert M, Delamarre L, Hartley A, Mellman I. Surface expression of MHC class II in dendritic cells is controlled by regulated ubiquitination. Nature. 2006;444:115-8. (Pubitemid 44684767)
60. Ohmura-Hoshino M, Matsuki Y, Mito-Yoshida M, Goto E, Aoki-Kawasumi M, Nakayama M, Ohara O, Ishido S. Cutting edge: Requirement of MARCH-I-mediated MHC II ubiquitination for the maintenance of conventional dendritic cells. J Immunol. 2009;183:6893-7.
61. McGehee AM, Strijbis K, Guillen E, Eng T, Kirak O, Ploegh HL. Ubiquitin-dependent control of class II MHC localization is dispensable for antigen presentation and antibody production. PLoS One. 2011;6:e18817.
62. Matsuki Y, Ohmura-Hoshino M, Goto E, Aoki M, Mito-Yoshida M, Uematsu M, Hasegawa T, Koseki H, Ohara O, Nakayama M, Toyooka K, Matsuoka K, Hotta H, Yamamoto A, Ishido S. Novel regulation of MHC class II function in B cells. EMBO J. 2007;26:846-54.
63. De Gassart A, Camosseto V, Thibodeau J, Ceppi M, Catalan N, Pierre P, Gatti E. MHC class II stabilization at the surface of human dendritic cells is the result of maturation-dependent MARCH I down-regulation. Proc Natl Acad Sci USA. 2008;105: 3491-6. (Pubitemid 351723580)
64. Thibodeau J, Bourgeois-Daigneault MC, Huppe G, Tremblay J, Aumont A, Houde M, Bartee E, Brunet A, Gauvreau ME, de Gassart A, Gatti E, Baril M, Cloutier M, Bontron S, Fruh K, Lamarre D, Steimle V. Interleukin-10-induced MARCH1 mediates intracellular sequestration of MHC class II in monocytes. Eur J Immunol. 2008;38:1225-30.
65. Walseng E, Furuta K, Bosch B, Weih KA, Matsuki Y, Bakke O, Ishido S, Roche PA. Ubiquitination regulates MHC class IIpeptide complex retention and degradation in dendritic cells. Proc Natl Acad Sci USA. 2010;107:20465-70.
66. van Niel G, Wubbolts R, Stoorvogel W. Endosomal sorting of MHC class II determines antigen presentation by dendritic cells. Curr Opin Cell Biol. 2008;20:437-44.
67. Hackett CJ, Horowitz D, Wysocka M, Eisenlohr LC. Immunogenic peptides of influenza virus subtype N1 neuraminidase identify a T-cell determinant used in class II major histocompatibility complex-restricted responses to infectious virus. J Virol. 1991;65:672-6.
68. Eisenlohr LC, Hackett CJ. Class II major histocompatibility complex-restricted T cells specific for a virion structural protein that do not recognize exogenous influenza virus. J Exp Med. 1989;169:921-31.
69. Jacobson S, Sekaly RP, Jacobson CL, McFarland HF, Long EO. HLA class II restricted presentation of cytoplasmic measles virus antigens to cytotoxic T cells. J Virol. 1989;63:1756-62. (Pubitemid 19085990)
70. Malnati MS, Marti M, LaVaute T, Jaraquemada D, Biddison W, DeMars R, Long EO. Processing pathways for presentation of cytosolic antigen to MHC class II-restricted T cells. Nature. 1992;357:702-4.
71. Pinet V, Malnati MS, Long EO. Two processing pathways for the MHC class II-restricted presentation of exogenous influenza virus antigen. J Immunol. 1994;152:4852-60. (Pubitemid 24139078)
72. Munthe LA, Kyte JA, Bogen B. Resting small B cells present endogenous immunoglobulin variable-region determinants to idiotope-specific CD4(?) T cells in vivo. Eur J Immunol. 1999;29:4043-52.
73. Baggi F, Nicolle M, Vincent A, Matsuo H, Willcox N, Newsom- Davis J. Presentation of endogenous acetylcholine receptor epitope by an MHC class II-transfected human muscle cell line to a specific CD4+ T cell clone from a myasthenia gravis patient. J Neuroimmunol. 1993;46:57-65.
74. Loss GE Jr, Elias CG, Fields PE, Ribaudo RK, McKisic M, Sant AJ. Major histocompatibility complex class II-restricted presentation of an internally synthesized antigen displays cell-type variability and segregates from the exogenous class II and endogenous class I presentation pathways. J Exp Med. 1993;178: 73-85. (Pubitemid 23173244)
75. Calin-Laurens V, Forquet F, Lombard-Platet S, Bertolino P, Chretien I, Trescol-Biemont MC, Gerlier D, Rabourdin-Combe C. High efficiency of endogenous antigen presentation by MHC class II molecules. Int Immunol. 1992;4:1113-21.
76. Moreno J,VignaliDAA,Nadimi F, Fuchs S,AdoriniL,Hämmerling GJ. Processing of an endogenous protein can generateMHCclass IIrestricted T cell determinants distinct from those derived from exogenous antigen. J Immunol. 1991;147:3306-13.
77. Crotzer VL, Blum JS. Autophagy and adaptive immunity. Immunology. 2010;131:9-17.
78. Munz C. Antigen processing via autophagy-not only for MHC class II presentation anymore? Curr Opin Immunol. 2010;22: 89-93.
79. Tewari MK, Sinnathamby G, Rajagopal D, Eisenlohr LC. A cytosolic pathway for MHC class II-restricted antigen processing that is proteasome and TAP dependent. Nat Immunol. 2005;6:287-94. (Pubitemid 41724766)
80. Bijlmakers M-JJE, Benaroch P, Ploegh Hl. Assembly of HLA DR1 molecules translated in vitro: Binding of peptide in the endoplasmic reticulum precludes association with invariant chain. EMBO J. 1994;13:2699-707. (Pubitemid 24188403)
81. Busch R, Yturina IY, Drexler J, Momburg F, Hämmerling GJ. Poor loading of major histocompatibility complex class II molecules with endogenously synthesized short peptides in the absence of invariant chain. Eur J Immunol. 1995;25:48-53.
82. Aichinger G, Karlsson L, Jackson MR, Vestberg M, Vaughan JH, Teyton L, Lechler RI, Peterson PA. Major histocompatibility complex class II-dependent unfolding, transport, and degradation of endogenous proteins. J Biol Chem. 1997;272: 29127-36.
83. Dodi AI, Brett S, Nordeng T, Sidhu N, Batchelor RJ, Lombardi G, Bakke O, Lechler RI. The invariant chain inhibits presentation of endogenous antigens by a human fibroblast cell line. Eur J Immunol. 1994;24:1632-9.
84. Lightstone L, Hargreaves R, Bobek G, Peterson M, Aichinger G, Lombardi G, Lechler R. In the absence of the invariant chain, HLA-DR molecules display a distinct array of peptides which is influenced by the presence or absence of HLA-DM. Proc Natl Acad Sci USA. 1997;94:5772-7.
85. Armstrong TD, Clements VK, Martin BK, Ting JP, Ostrand- Rosenberg S. Major histocompatibility complex class II-transfected tumor cells present endogenous antigen and are potent inducers of tumor-specific immunity. Proc Natl Acad Sci USA. 1997;94:6886-91. (Pubitemid 27281960)
86. Frauwirth K, Shastri N. Introducing endogenous antigens into the major histocompatibility complex (MHC) class II presentation pathway. Both Ii mediated inhibition and enhancement of endogenous peptide/MHC class II presentation require the same Ii domains. Immunology. 2001;102:405-15.
87. Lu X, Wu S, Blackwell CE, Humphreys RE, von Hofe E, Xu M. Suppression of major histocompatibility complex class II-associated invariant chain enhances the potency of an HIV gp120 DNA vaccine. Immunology. 2007;120:207-16. (Pubitemid 46046320)
88. Reay PA, Wettstein DA, Davis MM. pH dependence and exchange of high and low responder peptides binding to a class II MHC molecule. EMBO J. 1992;11:2829-39.
89. Nijenhuis M, Neefjes J. Early events in the assembly of major histocompatibility complex class II heterotrimers from their free subunits. Eur J Immunol. 1994;24:247-56. (Pubitemid 24014707)
90. Demotz S, Grey HM, Sette A. The minimal number of class II MHC-antigen complexes needed for T cell association. Science. 1990;249:1028-30.
91. Harding CV, Unanue ER. Quantitation of antigen-presenting cell MHC class II/peptide complexes necessary for T-cell stimulation. Nature. 1991;346:574-6.
92. Irvine DJ, Purbhoo MA, Krogsgaard M, Davis MM. Direct observation of ligand recognition by T cells. Nature. 2002; 419:845-9. (Pubitemid 35238571)
93. Burgdorf S, Scholz C, Kautz A, Tampe R, Kurts C. Spatial and mechanistic separation of cross-presentation and endogenous antigen presentation. Nat Immunol. 2008;9:558-66. (Pubitemid 351560525)
94. Comber JD, Robinson TM, Siciliano NA, Snook AE, Eisenlohr LC. Functional macroautophagy induction by influenza A virus without a contribution to major histocompatibility complex class II-restricted presentation. J Virol. 2011;85:6453-63.
95. He C, Klionsky DJ. Regulation mechanisms and signaling pathways of autophagy. Annu Rev Genet. 2009;43:67-93.
96. Gannage M, Munz C. Autophagy in MHC class II presentation of endogenous antigens. Curr Top Microbiol Immunol. 2009;335: 123-40.
97. Lee HK, Mattei LM, Steinberg BE, Alberts P, Lee YH, Chervonsky A, Mizushima N, Grinstein S, Iwasaki A. In vivo requirement for Atg5 in antigen presentation by dendritic cells. Immunity. 2010;32:227-39.
98. Kwun HJ, da Silva SR, Shah IM, Blake N, Moore PS, Chang Y. Kaposi's sarcoma-associated herpesvirus latency-associated nuclear antigen 1 mimics Epstein-Barr virus EBNA1 immune evasion through central repeat domain effects on protein processing. J Virol. 2007;81:8225-35. (Pubitemid 47101508)
99. Levitskaya J, Coram M, Levitsky V, Imreh S, Steigerwald- Mullen PM, Klein G, Kurilla MG, Masucci MG. Inhibiton of antigen processing by the internal repeat region of the Epstein- Barr virus nuclear antigen-1. Nature. 1995;375:685-8.
100. Levitskaya J, Sharipo A, Leonchiks A, Ciechanover A, Masucci MG. Inhibition of ubiquitin/proteasome-dependent protein degradation by the Gly-Ala repeat domain of the Epstein-Barr virus nuclear antigen 1. Proc Natl Acad Sci USA. 1997;94:12616-21. (Pubitemid 27492577)
101. Zaldumbide A, Ossevoort M, Wiertz EJ, Hoeben RC. In cis inhibition of antigen processing by the latency-associated nuclear antigen I of Kaposi sarcoma herpes virus. Mol Immunol. 2007;44:1352-60. (Pubitemid 44415957)
102. Ravikumar B, Duden R, Rubinsztein DC. Aggregate-prone proteins with polyglutamine and polyalanine expansions are degraded by autophagy. Hum Mol Genet. 2002;11:1107-17. (Pubitemid 34521091)
103. Webb JL, Ravikumar B, Atkins J, Skepper JN, Rubinsztein DC. Alpha-Synuclein is degraded by both autophagy and the proteasome. J Biol Chem. 2003;278:25009-13. (Pubitemid 37548663)
104. Cuervo AM. Chaperone-mediated autophagy: Selectivity pays off. Trends Endocrinol Metab. 2010;21:142-50.
105. Wing SS, Chiang HL, Goldberg AL, Dice JF. Proteins containing peptide sequences related to Lys-Phe-Glu-Arg-Gln are selectively depleted in liver and heart, but not skeletal muscle, of fasted rats. Biochem J. 1991;275(Pt 1):165-9.
106. Lich JD, Elliott JF, Blum JS. Cytoplasmic processing is a prerequisite for presentation of an endogenous antigen by major histocompatibility complex class II proteins. J Exp Med. 2000; 191:1513-24.
107. Crotzer VL, Blum JS. Autophagy and intracellular surveillance: Modulating MHC class II antigen presentation with stress. Proc Natl Acad Sci USA. 2005;102:7779-80. (Pubitemid 40781014)
108. Zhou D, Li P, Lin Y, Lott JM, Hislop AD, Canaday DH, Brutkiewicz RR, Blum JS. Lamp-2a facilitates MHC class II presentation of cytoplasmic antigens. Immunity. 2005;22: 571-81. (Pubitemid 40719193)
109. Todde V, Veenhuis M, van der Klei IJ. Autophagy: Principles and significance in health and disease. Biochim Biophys Acta. 2009;1792:3-13.
110. Weiss S, Bogen B. B-lymphoma cells process and present their endogenous immunoglobulin to major histocompatibility complex- restricted T cells. Proc Natl Acad Sci USA. 1989;86:282-6. (Pubitemid 19036370)
111. Weiss S, Bogen B. MHC class II-restricted presentation of intracellular antigen. Cell. 1991;64:767-76. (Pubitemid 121001164)
112. Nuchtern JG, Biddison WE, Klausner RD. Class II MHC molecules can use the endogenous pathway of antigen presentation. Nature. 1990;343:74-6.
113. Brooks A, Hartley S, Kjer-Nielsen L, Perera J, Goodenow CG, Basten A, McCluskey J. Class II-restricted presentation of an endogenously derived immunodominant T-cell determinant of hen egg lysozyme. Proc Natl Acad Sci USA. 1991;88:3290-4. (Pubitemid 21916606)
114. Silva CL, Palacios A, Colston MJ, Lowrie DB. Mycobacterium leprae 65hsp antigen expressed from a retroviral vector in a macrophage cell line is presented to T cells in association with MHC class II in addition to MHC class I. Microb Pathog. 1992;12:27-38.
115. Brooks AG, McCluskey J. Class II-restricted presentation of a hen egg lysozyme determinant derived from endogenous antigen sequestered in the cytoplasm or endoplasmic reticulum of the antigen poresenting cell. J Immunol. 1993;150:3690-7. (Pubitemid 23129750)
116. Lombard-Platet S, Bertolino P, Gimenez C, Humbert M, Gerlier D, Rabourdin-Combe C. Invariant chain expression similarly controls presentation of endogenously synthesized and exogenous antigens by MHC class II molecules. Cell Immunol. 1993; 148:60-70. (Pubitemid 23159733)
117. Callahan KM, Rowell JF, Soloski MJ, Machamer CE, Siliciano RF. HIV-1 envelope protein is expressed on the surface of infected cells before its processing and presentation to class IIrestricted T lymphocytes. J Immunol. 1993;151:2928-42. (Pubitemid 23282606)
118. Malnati MS, Ceman S, Weston M, DeMars R, Long EO. Presentation of cytosolic antigen by HLA-DR requires a function encoded in the class II region of the MHC. J Immunol. 1993; 151:6751-6.
119. Lombard-Platlet S, Bertolino P, Deng H, Gerlier D, Rabourdin- Combe C. Inhibition by chloroquine of the class II major histocompatibility complex-restricted presentation of endogenous antigens varies according to the cellular origin of the antigenpresenting cells, the nature of the T-cell epitope, and the responding T cell. Immunology. 1993;80:566-73. (Pubitemid 24010116)
120. Wysocka M, Eisenlohr LC, Otvos L Jr, Horowitz D, Yewdell JW, Bennink JR, Hackett CJ. Identification of overlapping class I and class II H-2d-restricted T cell determinants of influenza virus N1 neuraminidase that require infectious virus for presentation. Virology. 1994;201:86-94.
121. Chen PW, Ullrich SE, Ananthaswamy HN. Presentation of endogenous tumor antigens to CD4+ T lymphocytes by murine melanoma cells transfected with major histocompatibility complex class II genes. J Leukoc Biol. 1994;56:469-74. (Pubitemid 24319907)
122. Oxenius A, Bachmann MF, Ashton-Rickardt PG, Tonegawa S, Zinkernagel RM, Hengartner H. Presentation of endogenous viral proteins in association with major histocompatibility complex class II: On the role of intracellular compartmentalization, invariant chain and the TAP transporter system. Eur J Immunol. 1995;25:3402-11.
123. Gueguen M, Long EO. Presentation of a cytosolic antigen by major histocompatibility complex class II molecules requires a long-lived form of the antigen. Proc Natl Acad Sci USA. 1996; 93:14692-7. (Pubitemid 26419030)
124. Kima PE, Soong L, Chicharro C, Ruddle NH, McMahon-Pratt D. Leishmania-infected macrophages sequester endogenously synthesized parasite antigens from presentation to CD4+ T cells. Eur J Immunol. 1996;26:3163-9. (Pubitemid 26411527)
125. Parra-Lopez CA, Lindner R, Vidavsky I, Gross M, Unanue ER. Presentation on class II MHC molecules of endogenous lysozyme targeted to the endocytic pathway. J Immunol. 1997;158: 2670-9. (Pubitemid 127470524)
126. Lippolis JD, Denis-Mize KS, Brinckerhoff LH, Slingluff CL Jr, Galloway DR, Engelhard VH. Pseudomonas exotoxin-mediated delivery of exogenous antigens to MHC class I and class II processing pathways. Cell Immunol. 2000;203:75-83.
127. Qi L, Ostrand-Rosenberg S. MHC class II presentation of endogenous tumor antigen by cellular vaccines depends on the endocytic pathway but not H2-M. Traffic. 2000;1:152-60.
128. Topalian SL, Gonzales MI, Ward Y, Wang X, Wang RF. Revelation of a cryptic major histocompatibility complex class IIrestricted tumor epitope in a novel RNA-processing enzyme. Cancer Res. 2002;62:5505-9.
129. Beninga J, Rock KL, Goldberg AL. Interferon-gamma can stimulate post-proteasomal trimming of the N terminus of an antigenic peptide by inducing leucine aminopeptidase. J Biol Chem. 1998;273:18734-42. (Pubitemid 28366257)
130. York IA, Goldberg AL, Mo XY, Rock Kl. Proteolysis and class I major histocompatibility complex antigen presentation. Immunol Rev. 1999;172:49-66. (Pubitemid 30000468)
131. Fruh K, Yang Y. Antigen presentation by MHC class I and its regulation by interferon gamma. Curr Opin Immunol. 1999;11: 76-81. (Pubitemid 29082341)
132. Hammer GE, Gonzalez F, Champsaur M, Cado D, Shastri N. The aminopeptidase ERAAP shapes the peptide repertoire displayed by major histocompatibility complex class I molecules. Nat Immunol. 2006;7:103-12. (Pubitemid 41823874)
133. Hammer GE, Gonzalez F, James E, Nolla H, Shastri N. In the absence of aminopeptidase ERAAP, MHC class I molecules present many unstable and highly immunogenic peptides. Nat Immunol. 2007;8:101-8.
134. Testa JS, Apcher GS, Comber JD, Eisenlohr LC. Exosomedriven antigen transfer for MHC class II presentation facilitated by the receptor binding activity of influenza hemagglutinin. J Immunol. 2010;185:6608-16.
135. Lee P, Matsueda GR, Allen PM. T cell recognition of fibrinogen. A determinant on the Aa-chain does not require processing. J Immunol. 1988;140:1063-8. (Pubitemid 18088567)
136. Runnels HA, Weber DA, Moore JC, Westerman LE, Jensen PE. Intact proteins can bind to class II histocompatibility molecules with high affinity. Mol Immunol. 1997;34:471-80. (Pubitemid 27373713)
137. Watts C, Matthews SP, Mazzeo D, Manoury B, Moss CX. Asparaginyl endopeptidase: Case history of a class II MHC compartment protease. Immunol Rev. 2005;207:218-28. (Pubitemid 41415020)
138. Varghese JN, Laver WG, Colman PM. Structure of the influenza virus glycoprotein antigen neuraminidase at 2.9 A °resolution. Nature. 1983;303:35-40. (Pubitemid 13125070)
139. Lechner F, Wong DK, Dunbar PR, Chapman R, Chung RT, Dohrenwend P, Robbins G, Phillips R, Klenerman P, Walker BD. Analysis of successful immune responses in persons infected with hepatitis C virus. J Exp Med. 2000;191:1499-512. (Pubitemid 30257347)
140. Shoukry NH, Cawthon AG, Walker CM. Cell-mediated immunity and the outcome of hepatitis C virus infection. Annu Rev Microbiol. 2004;58:391-424. (Pubitemid 39551992)
141. O'Garra A, Steinman L, Gijbels K. CD4 ? T-cell subsets in autoimmunity. Curr Opin Immunol. 1997;9:872-83.
142. Ostrand-Rosenberg S. CD4 ? T lymphocytes: A critical component of antitumor immunity. Cancer Invest. 2005;23:413-9. (Pubitemid 41324359)